Immune checkpoint inhibition (ICI) has transformed the management of metastatic colorectal cancer (mCRC) with mismatch-repair deficiency (dMMR) and microsatellite instability (MSI-H), though this constitutes on average less than 5% of mCRC, and ICI is ineffective in preserved MMR/microsatellite stable disease (pMMR/MSS). Here we review the efficacy of ICI in dMMR/MSI-H mCRC, poor response to ICI in pMMR/MSS mCRC, role for ICI in locally advanced disease, biomarkers of response, novel immunotherapies, and future directions in targeting resistance mechanisms.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/jso.26357 | DOI Listing |
Publication Analysis
Top Keywords
colorectal cancer
8
ici
5
immunotherapy treatment
4
treatment colorectal
4
cancer immune
4
immune checkpoint
4
checkpoint inhibition
4
inhibition ici
4
ici transformed
4
transformed management
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!